Description of cardiovascular remodeling parameters and osteopontin plasma level in dynamics of the candesartan therapy in patients with chronic kidney disease on the stage before dialysis
DOI:
https://doi.org/10.14739/2310-1210.2015.2.42002Keywords:
Сhronic Renal Insufficiency, Ventricular Hypertrophy, Carotid Intima-Media Thickness, Osteopontin, CandesartanAbstract
Aim. To examine the cardiovascular remodeling parameters and osteopontin plasma level in dynamics of the candesartan therapy in patients with chronic kidney disease on the stage before dialysis
Methods and results. Peculiarities of the cardiovascular remodeling were studied in 52 patients with chronic kidney disease III, IV, and V stage. Echocardiography, carotid dopplerography, and immunoassay detection of the osteopontin level were done. The predominant type of pathological left ventricular geometry was concentric hypertrophy, its prevalence increased with worsening of the renal function. The maximum level of IMT was observed at stage V of the CKD. The chronic kidney disease progression was accompanied by increased plasma levels of the osteopontin.
Conclusion. Direct correlation between the concentration of the protein and the index of left ventricular mass and the intima-media thickness were detected. The therapy with candesartan during 12 weeks leads to the significant reduction of osteopontin, which can be considered as a marker of cardiovascular remodeling in patients with CKD.References
Korotkiy, D. V., Makeeva, T. I., Zavaritskaya, O. P., & Zemchenkov, A. Yu. (2009) Arterial'naya gipertenziya i gipertrofiya miokarda na preddializnoj stadii khronicheskoj bolezni pochek i pri zamestitel'noj pochechnoj terapii [Hypertension and left ventricular hypertrophy in patients with predialysis CKD stages and on renal replacement therapy]. Nefrologiya i dializ, 3(11), 35–47. [in Russian].
Bikbov, B. T., & Tomilina, N. A. (2009) Sostoyanie zamestitel'noj terapii bol'nykh s khronicheskoj pochechnoj nedostatochnost'yu v Rossijskoj federacii v 1998–2007 gg.: analiticheskij otchet po dannym Rossijskogo registra zamestitel'noj pochechnoj terapii [Status of renal replacement therapy in ESRD patients of Russian Federation in 1998-2007 Analytic report of Russian RRT Register]. Nefrologiya i dializ, 3(11), 144–233. [in Russian].
Kolesnyk, M. O., Saidakova, N. O., Kozliuk, N. І., & Nіkolaienko, S. S. (2013) Medyko-profilaktychna dopomoha khvorym nefrolohichnoho profiliu 2009–2012, shcho robyty dali? [Medical and preventive care to patients Nephrology Profile 2009-2012 to do more?] Ukrainskyi zhurnal nefrolohii i dializu, 3(39) Retrieved from http://ukrjnd.com.ua/pages/view/170. [in Ukrainian].
Kozliuk, N. І., Nіkolaienko, S. S., & Kulyzkyi, M. V. (2013) Natsіonalnyi reiestr khvorykh na khronіchnu khvorobu nyrok: 2012 rіk [National registry of patients with chronic kidney disease: 2012] M.O. Kolesnyk (Ed.). Kyiv. [in Ukrainian].
Sakurabayashi, K. S., Aoka, Y., Nagashima, H., Kasanuki, H., Hagiwara, N., & Kawana, M. (2009) Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling inangiotensin II overproducing transgenic mice. Atherosclerosis, 206(1), 54–60. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2009.01.039
Grau, J. B., Poggio, P., Sainger, R. Vernick, W., Seefried, W. F., Branchetti, E., et al. (2012) Analysis of Osteopontin Levels for the Identification of Asymptomatic Patients with Calcific Aortic Valve Disease. Ann. Thoracic Surg., 93(1), 79–86. doi: 10.1016/j.athoracsur.2011.08.036.
Kurata, M., Okura, T., Irita, J., Enomoto, D., Nagao, T., Jotoku, M., et al. (2011) Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J. Hum. Hypertens, 25(5), 334–339. doi: 10.1038/jhh.2010.73.
Lorenzen, M., Neunhöffer, H., David, S., Kielstein, J. T., Haller, H., Fliser, D. (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis, 209(1), 184–188. doi: 10.1016/j.atherosclerosis.2009.09.009
Ricardo, S. D., Franzoni, D. F., Roesener, C. D., Crisman, J. M., Diamond, J. R. (2000) Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. Am. J. Physiol. Renal Physiol, 278(1), 708–716.
Nakayama, H., Nagai, H., Matsumoto, K., Oguro, R., Sugimoto, K., Kamide, K., et al. (2011) Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population. Hypertens. Res., 34(10), 1141–1146. doi: 10.1038/hr.2011.102.
Cockcroft, D. W., & Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron., 16(1), 31–41. doi:10.1159/000180580.
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., Reichek, N. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol., 57, 450–458.
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., et al. (2013) ESH/ESC Guidelines for the management of arterial hypertension. 2013. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 31, 1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc.
Floege, J., Kim, J., Ireland, E., Chazot, C., Drueke, T., de Francisco, A., et al. (2011) iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol. Dial. Transplant., 26, 1948–1955. doi: 10.1093/ndt/gfq219.
Singh, K., Sirokman, G., Communal, C., Robinson, K. G., Conrad, C. H., et al. (1999) Myocardial osteopontin expression coincides with the development of heart failure. Hypertension, 33, 663–670.
Soundarapandian Vijayakumar (Ed.) (2012). Novel Insights on Chronic Kidney Disease, Acute Kidney Injury and Polycystic Kidney Disease. Publisher InTech.
Min Wu, Ri-Ning Tang, Min Gao, et al. (2012) Parathyroid hormone induces endothelial-to-mesenchymal transition in human aortic endothelial cells. Nephrol. Dial. Transplant., 27(2), 227–251.
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., et al. (2003) SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens, 21(5), 875–886.
(2011) Bethesda. US Renal Data System: USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Zahradka, P. (2008) Novel role for osteopontin in cardiac fibrosis. Circ. Res., 102(3), 270–272. doi: 10.1161/CIRCRESAHA.107.170555.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
